Reassessing the Performance of the "Step-By-Step" Approach to Febrile Infants 90 Days of Age and Younger in the Context of the COVID-19 Pandemic: A Multicentric Retrospective Study.


Journal

The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858

Informations de publication

Date de publication:
01 09 2022
Historique:
pubmed: 16 6 2022
medline: 12 8 2022
entrez: 15 6 2022
Statut: ppublish

Résumé

Infants with COVID-19 can often present with fever without source, which is a challenging situation in infants <90 days old. The "step-by-step" algorithm has been proposed to identify children at high risk of bacterial infection. In the context of the COVID-19 pandemic, we aimed to reassess the diagnostic performance of this algorithm. We performed a multicentric retrospective study in 3 French pediatric emergency departments between 2018 and 2020. We applied the "step-by-step" algorithm to 4 clinical entities: COVID-19, febrile urinary tract infections (FUTI), invasive bacterial infection (IBI), and enterovirus infections. The main outcome was the proportion of infants classified at high risk (ill-appearing, ≤21 days old, with leukocyturia or procalcitonin level ≥0.5 ng/mL). Among the 199 infants included, 40 had isolated COVID-19, 25 had IBI, 60 had FUTI, and 74 had enterovirus infection. All but 1 infant with bacterial infection were classified at high risk (96% for IBI and 100% for FUTI) as well as 95% with enterovirus and 82% with COVID-19. Infants with COVID-19 were classified at high risk because an ill-appearance (72%), an age ≤21 days (27%), or leukocyturia (19%). All these infants had procalcitonin values <0.5 ng/mL and only 1 had C-reactive protein level >20 mg/L. The "step-by-step" algorithm remains effective to identify infants with bacterial infection but misclassifies most infants with COVID-19 as at high risk of bacterial infection leading to unnecessary cares. An updated algorithm based adding viral testing may be needed to discriminate fever related to isolated COVID-19 in infants <90 days old.

Sections du résumé

BACKGROUND
Infants with COVID-19 can often present with fever without source, which is a challenging situation in infants <90 days old. The "step-by-step" algorithm has been proposed to identify children at high risk of bacterial infection. In the context of the COVID-19 pandemic, we aimed to reassess the diagnostic performance of this algorithm.
METHODS
We performed a multicentric retrospective study in 3 French pediatric emergency departments between 2018 and 2020. We applied the "step-by-step" algorithm to 4 clinical entities: COVID-19, febrile urinary tract infections (FUTI), invasive bacterial infection (IBI), and enterovirus infections. The main outcome was the proportion of infants classified at high risk (ill-appearing, ≤21 days old, with leukocyturia or procalcitonin level ≥0.5 ng/mL).
RESULTS
Among the 199 infants included, 40 had isolated COVID-19, 25 had IBI, 60 had FUTI, and 74 had enterovirus infection. All but 1 infant with bacterial infection were classified at high risk (96% for IBI and 100% for FUTI) as well as 95% with enterovirus and 82% with COVID-19. Infants with COVID-19 were classified at high risk because an ill-appearance (72%), an age ≤21 days (27%), or leukocyturia (19%). All these infants had procalcitonin values <0.5 ng/mL and only 1 had C-reactive protein level >20 mg/L.
CONCLUSIONS
The "step-by-step" algorithm remains effective to identify infants with bacterial infection but misclassifies most infants with COVID-19 as at high risk of bacterial infection leading to unnecessary cares. An updated algorithm based adding viral testing may be needed to discriminate fever related to isolated COVID-19 in infants <90 days old.

Identifiants

pubmed: 35703301
doi: 10.1097/INF.0000000000003614
pii: 00006454-202209000-00018
pmc: PMC9359674
doi:

Substances chimiques

Procalcitonin 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e365-e368

Informations de copyright

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors have no funding or conflicts of interest to disclose.

Références

Milcent K, Faesch S, Gras-Le Guen C, et al. Use of procalcitonin assays to predict serious bacterial infection in young febrile infants. JAMA Pediatr. 2016;170:62–69.
Mintegi S, Bressan S, Gomez B, et al. Accuracy of a sequential approach to identify young febrile infants at low risk for invasive bacterial infection. Emerg Med J. 2014;31(e1):e19–e24.
Pantell RH, Roberts KB, Adams WG, et al.; Subcommittee on Febrile Infants. Evaluation and management of well-appearing febrile infants 8 to 60 days old. Pediatrics. 2021;148:e2021052228.
Hubert G, Launay E, Feildel Fournial C, et al. Assessment of the impact of a new sequential approach to antimicrobial use in young febrile children in the emergency department (DIAFEVERCHILD): a French prospective multicentric controlled, open, cluster-randomised, parallel-group study protocol. BMJ Open. 2020;10:e034828.
Gomez B, Mintegi S, Bressan S, et al.; European Group for Validation of the Step-by-Step Approach. Validation of the “Step-by-Step” approach in the management of young febrile infants. Pediatrics. 2016;138:e20154381.
de Crom SC, van Furth MA, Peeters MF, et al. Characteristics of pediatric patients with enterovirus meningitis and no cerebral fluid pleocytosis. Eur J Pediatr. 2012;171:795–800.
de Crom SC, Rossen JW, van Furth AM, et al. Enterovirus and parechovirus infection in children: a brief overview. Eur J Pediatr. 2016;175:1023–1029.
Mark EG, Golden WC, Gilmore MM, et al. Community-onset severe acute respiratory syndrome coronavirus 2 infection in young infants: a systematic review. J Pediatr. 2021;228:94–100.e3.
Bellini T, Rotulo GA, Caruggi S, et al. Characteristics of COVID-19 patients up to 6 months of age admitted to a paediatric emergency department. Acta Paediatr. 2022;111:272–274.
Dieckmann RA, Brownstein D, Gausche-Hill M. The pediatric assessment triangle: a novel approach for the rapid evaluation of children. Pediatr Emerg Care. 2010;26:312–315.
Gelman A, Hill J, Yajima M. Why we (Usually) don’t have to worry about multiple comparisons. J Res Educ Eff. 2012;5:189–211.
Veneti L, Boas H, Brathen Kristoffersen A, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Euro Surveill. 2022;27.

Auteurs

Alexis Rybak (A)

From the Pediatric Emergency Department, Robert Debré University Hospital, Université de Paris, Assistance Publique-Hôpitaux de Paris, Paris, France.

Camille Aupiais (C)

INSERM, Unité Mixte de Recherche 1123 Epidémiologie Clinique et Évaluation Économique Appliquées aux Populations Vulnérables (ECEVE), Université de Paris, Paris, France.

Marie Cotillon (M)

Department of Pediatrics, Louis Mourier University Hospital, Université de Paris, Assistance Publique-Hôpitaux de Paris, Colombes, France.

Romain Basmaci (R)

Department of Pediatrics, Louis Mourier University Hospital, Université de Paris, Assistance Publique-Hôpitaux de Paris, Colombes, France.

Loïc de Pontual (L)

Department of Pediatrics, Jean Verdier University Hospital, Assistance Publique-Hôpitaux de Paris, Université Sorbonne Paris Nord, Bondy, France.

Stéphane Bonacorsi (S)

INSERM, Unité Mixte de Recherche 1137 Infection-Antimicrobials-Modelling-Evolution (IAME), Université de Paris, Paris, France.

Patricia Mariani (P)

Department of Microbiology, Robert Debré University Hospital, Université de Paris, Assistance Publique-Hôpitaux de Paris, Paris, France.

Luce Landraud (L)

Department of Microbiology, Louis Mourier University Hospital, Université de Paris, Assistance Publique-Hôpitaux de Paris, Colombes, France.

Ségolène Brichler (S)

Department of Clinical Microbiology, Paris-Seine-Saint-Denis University Hospitals, Université Sorbonne Paris Nord, Assistance Publique-Hôpitaux de Paris, Bobigny, France.

Isabelle Poilane (I)

Department of Clinical Microbiology, Paris-Seine-Saint-Denis University Hospitals, Université Sorbonne Paris Nord, Assistance Publique-Hôpitaux de Paris, Bobigny, France.

Naïm Ouldali (N)

Association Clinique et Thérapeutique Infantile du Val-de-Marne (ACTIV), Créteil, France.

Luigi Titomanlio (L)

From the Pediatric Emergency Department, Robert Debré University Hospital, Université de Paris, Assistance Publique-Hôpitaux de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH